
|Articles|December 14, 2021
Daily Medication Pearl: Gabapentin Enacarbil (Horizant)
Author(s)Saro Arakelians, PharmD
Gabapentin enacarbil treats moderate-to-severe primary restless leg syndrome and postherpetic neuralgia.
Advertisement
Medication Pearl of the Day: Gabapentin Enacarbil (Horizant)
Indication: Gabapentin enacarbil is indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and the management of postherpetic neuralgia (PHN) in adults.
Insight:
- Dosing: For RLS, 600 mg once daily taken at about 5 pm. A dose of 1200 mg once daily provided no additional benefit compared with the 600-mg dose, but caused an increase in adverse reactions.
 - Dosage forms: Extended-release tablets 300 mg and 600 mg.
 - Adverse events (AEs): Most common AEs (≥10% and at least 2 times the rate of placebo) were somnolence/sedation and dizziness.
 - Mechanism of action: Gabapentin prevents pain-related responses in several models of neuropathic pain in humans.
 - Manufacturer: Arbor Pharmaceuticals
 
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
Experimental Vaccine Shows 73% Efficacy Against Salmonella Paratyphi A
3
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
4
Pharmacists Key to Counseling and Monitoring Patients Transitioning to Low-Sodium Oxybate
5














































































































































































































